https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20763 Wed 11 Apr 2018 09:54:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24206 Thu 04 Nov 2021 10:38:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11280 35 kg/m2) at baseline had more recurrences than those women with a low BMI (BMI < 23 kg/m2; adjusted hazard ratio [HR], 1.39; 95% CI, 1.06 to 1.82; Pheterogeneity = .03) and significantly more distant recurrences (adjusted HR, 1.46; 95% CI, 1.07 to 1.61; Pheterogeneity = .01). Overall, the relative benefit of anastrozole versus tamoxifen was nonsignificantly better in thin women compared to overweight women. Conclusion: These results confirm the poorer prognosis of obese women with early-stage breast cancer. Recurrence rates were lower for anastrozole than tamoxifen for all BMI quintiles. Our results suggest that the relative efficacy of anastrozole compared to tamoxifen is greater in thin postmenopausal women and higher doses or more complete inhibitors might be more effective in overweight women, but this requires independent confirmation.]]> Sat 24 Mar 2018 08:12:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11225 Sat 24 Mar 2018 08:11:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11140 Sat 24 Mar 2018 08:10:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5127 Sat 24 Mar 2018 07:48:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5453 Sat 24 Mar 2018 07:48:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4862 30 kg/m²) reported more joint symptoms than women with a BMI of 25-30 kg/m² or those with a BMI <25 kg/m² (504 of 1354 women [37·2%] vs 502 of 1926 women [31·3%; OR 1·01 (0·88-1·16)] vs 592 of 1908 women [31·0%; OR 1·32 (1·14-1·53)]) and women on anastrozole reported more joint symptoms compared with those on tamoxifen (949 of 2698 women [35·2%] vs 829 of 2735 women [30·3%]; OR 1·25 [1·11-1·40]). All significant risk factors from the univariate analysis were included in a multivariate analysis and remained significant with little change. Interpretation: In this trial, the major risk factors for developing joint symptoms were previous HRT, hormone-receptor positivity, previous chemotherapy, obesity, and treatment with anastrozole. Discussion of identified risk factors is appropriate when counselling women before initiation of adjuvant hormonal treatment. Funding: This study was funded by Cancer Research UK and AstraZeneca (Macclesfield, UK).]]> Sat 24 Mar 2018 07:18:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32394 Mon 23 Sep 2019 11:45:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49499 Fri 19 May 2023 12:01:55 AEST ]]>